GLUE Monte Rosa Therapeutics Inc
224
$5.37
$0.31
(5.46%)
| Watchers | 224 |
| 52-Wk Low | $2.44 |
| 52-Wk High | $8.84 |
| Market Cap | $285.85M |
| Volume | 46,461.00 |
| 52-Wk High | $8.84 |
| 52-Wk Low | $2.44 |
Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial ResultsGuruFocus • about 2 months ago
Advances in Clinical Trials and Strategic Collaboration Mark Year's AchievementsRelated Stocks: GLUE...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose...
MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1 and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially...
For the last three days, A.I.dvisor has detected that GLUE's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
For the last three days, A.I.dvisor has detected that GLUE's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the company shows strong potential for value creation.
Latest Ratings for...